Literature DB >> 8830192

Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro.

P Anderson1, J Lötvall, A Lindén.   

Abstract

The mechanisms producing long duration of action for formoterol and salmeterol are not fully understood. The aim of the current study was to examine how the concentration of long and short acting beta 2-adrenoceptor agonists affects their relaxation kinetics in airway smooth muscle. Onset (time to peak relaxation) and offset of action (reassertion of reversible relaxation followed repeated beta-adrenoceptor blockade and washout) were measured in the guinea pig trachea precontracted postjunctionally by carbachol 0.3 microM in vitro. At 10-1,000% (C10-C1,000) of the maximally effective concentration (C100: 150 nM formoterol, 10 microM salbutamol, 30 microM salmeterol), salbutamol had a shorter time to peak relaxation than did salmeterol. Formoterol and salmeterol had a similar time to peak relaxation at C10, but, in contrast to salmeterol, formoterol's time to peak relaxation became markedly shorter and similar to that of salbutamol as the concentration was increased up to C1,000. Significant reversible reasserted relaxation was demonstrated for salmeterol alone at C10. At C30-C1,000, however, salmeterol produced irreversible relaxation only, in spite of repeated beta-adrenoceptor blockade by sotalol 10 microM followed by washout. In contrast, formoterol produced an increasing reversible reasserted relaxation at C30-C1,000. Salbutamol produced significant, reversible reasserted relaxation at C1,000 only. In conclusion, the concentration determines the onset and offset of action for formoterol and to a lesser extent for salbutamol, but not for salmeterol. To cause sustained action, a submaximally effective concentration is sufficient for salmeterol, whereas formoterol requires a maximally effective concentration. The rank order of concentration dependence for the relaxation kinetics is not paralleled by the rank order of lipophilicity for formoterol, salbutamol, and salmeterol. Therefore, factors other than lipophilicity may also play a role in determining the relationship between concentration and relaxation kinetics for the investigated beta 2-agonists.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830192     DOI: 10.1007/bf00173308

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  22 in total

1.  On the predictive value of experiments in vitro in the evaluation of the effect duration of bronchodilator drugs for local administration.

Authors:  A B Jeppsson; C G Löfdahl; B Waldeck; E Widmark
Journal:  Pulm Pharmacol       Date:  1989

Review 2.  Why are long-acting beta-adrenoceptor agonists long-acting?

Authors:  G P Anderson; A Lindén; K F Rabe
Journal:  Eur Respir J       Date:  1994-03       Impact factor: 16.671

Review 3.  Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma.

Authors:  C G Löfdahl; K F Chung
Journal:  Eur Respir J       Date:  1991-02       Impact factor: 16.671

4.  Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Allergy       Date:  1989-05       Impact factor: 13.146

5.  Formoterol and salmeterol are both long acting compared to terbutaline in the isolated perfused and ventilated guinea-pig lung.

Authors:  A B Jeppsson; E Nilsson; B Waldeck
Journal:  Eur J Pharmacol       Date:  1994-05-12       Impact factor: 4.432

6.  In vitro characteristics of spontaneous airway tone in the guinea-pig.

Authors:  A Lindén; C G Löfdahl; A Ullman; B E Skoogh
Journal:  Acta Physiol Scand       Date:  1991-07

7.  Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic.

Authors:  E Y Derom; R A Pauwels
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

8.  Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus.

Authors:  E Naline; Y Zhang; Y Qian; N Mairon; G P Anderson; B Grandordy; C Advenier
Journal:  Eur Respir J       Date:  1994-05       Impact factor: 16.671

9.  Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol.

Authors:  A T Nials; D I Ball; P R Butchers; R A Coleman; A A Humbles; M Johnson; C J Vardey
Journal:  Eur J Pharmacol       Date:  1994-01-14       Impact factor: 4.432

10.  Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig.

Authors:  T Sakamoto; P J Barnes; K F Chung
Journal:  Agents Actions       Date:  1993-09
View more
  3 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Clinical pharmacokinetics of salmeterol.

Authors:  Mario Cazzola; Renato Testi; Maria Gabriella Matera
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells.

Authors:  M G Scott; C Swan; T M Jobson; S Rees; I P Hall
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.